WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: Week 12-ACH, Injecting 0.6-1.0 mg IV atropine Mild or No toxicity if Pulse rate increases by 25 bpm, Depolarizing neuromuscular blocking drugs ex: drug succinylcholine, Train of four monitors neuromuscular junction, Nm receptors causing initial excitation action then persisting depolarization, Block ACh release from nerve ending Botulinum Toxin By inhibiting contraction, Organophosphates and Carbamate Poisioning Can be tested by Atropine Test, bind and inhibits muscarinic receptors which decreases the symptoms, Acetylcholinesterase Inhibition leads to Increased levels of Acetylcholine, Block ACh release from nerve ending Act peripherally at neuromuscular junction/ muscle fiber Ex. D-Tubocurarine, Vecuronium, Rocuronium, Doxacurium, Organophosphates and Carbamate Poisioning is treated with Atropine, Reversibly via ACHesterase inhibitors, Myasthenia Gravis symptoms facial paralysis, decreases the symptoms until organophosphate is metobolized and ACh gets cleaved by AChE, Non-depolarizing neuromuscular blocking drugs acts by competitive inhibiton at ACh receptors, 4 successive stimuli 2hz every 0.5 seconds measure t4/t1 ratio, 68.2-102.2 milligrams of Succinylcholine Onset of Action 60-90 seconds, 60-90 seconds Duration 8-12 minutes, Myasthenia Gravis symptoms difficulty to chew & swallow (jaw gets tired), Decrease in ACh binding to receptor by ACh inhibitors, Block nicotine receptor from ACh 2 mechanisms reversibly